131 related articles for article (PubMed ID: 38008041)
1. Glutathione-responsive PROTAC for targeted degradation of ERα in breast cancer cells.
Zhou Z; Fan H; Yu D; Shi F; Li Q; Zhang Z; Wang X; Zhang X; Dong C; Sun H; Mi W
Bioorg Med Chem; 2023 Dec; 96():117526. PubMed ID: 38008041
[TBL] [Abstract][Full Text] [Related]
2. Discovery of estrogen receptor α targeting caged hypoxia-responsive PROTACs with an inherent bicyclic skeleton for breast cancer treatment.
Xie B; Xu B; Xin L; Wei Y; Guo X; Dong C
Bioorg Chem; 2023 Aug; 137():106590. PubMed ID: 37163809
[TBL] [Abstract][Full Text] [Related]
3. Targeting steroid hormone receptors for ubiquitination and degradation in breast and prostate cancer.
Rodriguez-Gonzalez A; Cyrus K; Salcius M; Kim K; Crews CM; Deshaies RJ; Sakamoto KM
Oncogene; 2008 Dec; 27(57):7201-11. PubMed ID: 18794799
[TBL] [Abstract][Full Text] [Related]
4. Metabolism-driven in vitro/in vivo disconnect of an oral ERɑ VHL-PROTAC.
Hayhow TG; Williamson B; Lawson M; Cureton N; Braybrooke EL; Campbell A; Carbajo RJ; Cheraghchi-Bashi A; Chiarparin E; Diène CR; Fallan C; Fisher DI; Goldberg FW; Hopcroft L; Hopcroft P; Jackson A; Kettle JG; Klinowska T; Künzel U; Lamont G; Lewis HJ; Maglennon G; Martin S; Gutierrez PM; Morrow CJ; Nikolaou M; Nissink JWM; O'Shea P; Polanski R; Schade M; Scott JS; Smith A; Weber J; Wilson J; Yang B; Crafter C
Commun Biol; 2024 May; 7(1):563. PubMed ID: 38740899
[TBL] [Abstract][Full Text] [Related]
5. Selective degradation of BRD4 suppresses lung cancer cell proliferation using GSH-responsive PROTAC precursors.
Fan H; Zhou Z; Yu D; Sun J; Wang L; Jia Y; Tian J; Mi W; Sun H
Bioorg Chem; 2023 Nov; 140():106793. PubMed ID: 37683536
[TBL] [Abstract][Full Text] [Related]
6. Fluorescence theranostic PROTACs for real-time visualization of ERα degradation.
Wang X; Xin L; Deng X; Dong C; Hu G; Zhou HB
Eur J Med Chem; 2024 Mar; 267():116184. PubMed ID: 38320426
[TBL] [Abstract][Full Text] [Related]
7. Targeting estrogen receptor α for degradation with PROTACs: A promising approach to overcome endocrine resistance.
Lin X; Xiang H; Luo G
Eur J Med Chem; 2020 Nov; 206():112689. PubMed ID: 32829249
[TBL] [Abstract][Full Text] [Related]
8. Novel 11β-substituted estradiol conjugates: Transition from ERα agonizts to effective PROTAC degraders.
Luo G; Li X; Lin X; Lu X; Li Z; Xiang H
J Steroid Biochem Mol Biol; 2022 Oct; 223():106154. PubMed ID: 35870675
[TBL] [Abstract][Full Text] [Related]
9. Discovery of a Novel Class of PROTACs as Potent and Selective Estrogen Receptor α Degraders to Overcome Endocrine-Resistant Breast Cancer
Xie B; Yin Z; Hu Z; Lv J; Du C; Deng X; Huang Y; Li Q; Huang J; Liang K; Zhou HB; Dong C
J Med Chem; 2023 May; 66(10):6631-6651. PubMed ID: 37161783
[TBL] [Abstract][Full Text] [Related]
10. Targeted degradation of activating estrogen receptor α ligand-binding domain mutations in human breast cancer.
Gonzalez TL; Hancock M; Sun S; Gersch CL; Larios JM; David W; Hu J; Hayes DF; Wang S; Rae JM
Breast Cancer Res Treat; 2020 Apr; 180(3):611-622. PubMed ID: 32067153
[TBL] [Abstract][Full Text] [Related]
11. Development of Stabilized Peptide-Based PROTACs against Estrogen Receptor α.
Jiang Y; Deng Q; Zhao H; Xie M; Chen L; Yin F; Qin X; Zheng W; Zhao Y; Li Z
ACS Chem Biol; 2018 Mar; 13(3):628-635. PubMed ID: 29271628
[TBL] [Abstract][Full Text] [Related]
12. Development of cell-permeable peptide-based PROTACs targeting estrogen receptor α.
Dai Y; Yue N; Gong J; Liu C; Li Q; Zhou J; Huang W; Qian H
Eur J Med Chem; 2020 Feb; 187():111967. PubMed ID: 31865016
[TBL] [Abstract][Full Text] [Related]
13. PROTAC Degrader of Estrogen Receptor α Targeting DNA-Binding Domain in Breast Cancer.
Zhang X; Zhang Z; Xue X; Fan T; Tan C; Liu F; Tan Y; Jiang Y
ACS Pharmacol Transl Sci; 2022 Nov; 5(11):1109-1118. PubMed ID: 36407946
[TBL] [Abstract][Full Text] [Related]
14. Enhanced Tumor Targeting and Penetration of Proteolysis-Targeting Chimeras through iRGD Peptide Conjugation: A Strategy for Precise Protein Degradation in Breast Cancer.
He S; Fang Y; Wu M; Zhang P; Gao F; Hu H; Sheng C; Dong G
J Med Chem; 2023 Dec; 66(24):16828-16842. PubMed ID: 38055861
[TBL] [Abstract][Full Text] [Related]
15. Cancer Selective Target Degradation by Folate-Caged PROTACs.
Liu J; Chen H; Liu Y; Shen Y; Meng F; Kaniskan HÜ; Jin J; Wei W
J Am Chem Soc; 2021 May; 143(19):7380-7387. PubMed ID: 33970635
[TBL] [Abstract][Full Text] [Related]
16. Microneedle Patch Delivery of PROTACs for Anti-Cancer Therapy.
Cheng X; Hu S; Cheng K
ACS Nano; 2023 Jun; 17(12):11855-11868. PubMed ID: 37294705
[TBL] [Abstract][Full Text] [Related]
17. A novel selective estrogen receptor degrader induces cell cycle arrest in breast cancer via ERα degradation and the autophagy-lysosome pathway.
Zhou J; Shen R; Liu J; Deng X; Xin L; Zhou HB; Huang J
Bioorg Med Chem; 2023 Mar; 82():117235. PubMed ID: 36905762
[TBL] [Abstract][Full Text] [Related]
18. Structural Optimization of Decoy Oligonucleotide-Based PROTAC That Degrades the Estrogen Receptor.
Naganuma M; Ohoka N; Tsuji G; Inoue T; Naito M; Demizu Y
Bioconjug Chem; 2023 Oct; 34(10):1780-1788. PubMed ID: 37736001
[TBL] [Abstract][Full Text] [Related]
19. Clinician's guide to targeted estrogen receptor degradation using PROTAC in patients with estrogen receptor-positive metastatic breast cancer.
Grinshpun A
Curr Opin Oncol; 2023 Nov; 35(6):472-478. PubMed ID: 37427531
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]